Statin use and risk for ovarian cancer: A Danish nationwide case-control study

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 157-161

  Baandrup, L ^a   Dehlendorff, C ^a   Friis, S ^a   Olsen, J H ^a   Kjaer S K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

chemoprevention; ovarian cancer; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; CASE CONTROL STUDY; DENMARK; MIDDLE AGED; OVARIAN NEOPLASMS; REGISTER; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; OVARIAN NEOPLASMS; REGISTRIES; RISK;

EID: 84920688856     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.574     Document Type: Article

References (25)

1. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93.
2. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9: 603-621.
3. Chen J, Liu B, Yuan J, Yang J, Zhang J, An Y, Tie L, Pan Y, Li X (2012) Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production. Mol Oncol 6: 62-72.
4. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295: 74-80.
5. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart A (2009) Statin adherence and risk of accidents: a cautionary tale. Circulation 119: 2051-2057.
6. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry Jr. CP, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17: 27-36.
7. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M (2012) Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64: 102-146.
8. Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39(7 Suppl): 42-45.
9. Kaye JA, Jick H (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90: 635-637.
10. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39(7 Suppl): 38-41.
11. Klint A, Tryggvadottir L, Bray F, Gislum M, Hakulinen T, Storm HH, Engholm G (2010) Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 49: 632-643.
12. Kurman RJ, Shih I (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443.
13. Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G (2013) The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol 130: 615-619.
14. Liu H, Liang SL, Kumar S, Weyman CM, Liu W, Zhou A (2009) Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol 63: 997-1005.
15. Liu Y, Qin A, Li T, Qin X, Li S (2014) Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. Gynecol Oncol 133: 647-655.
16. Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T (2011) Statinmediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep 25: 41-47.
17. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39(7 Suppl): 22-25.
18. R Development Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria.
19. Riahi S, Fonager K, Toft E, Hvilsted-Rasmussen L, Bendsen J, Paaske JS, Soerensen HT (2001) Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark. Br J Clin Pharmacol 52: 307-311.
20. Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144: 363-372.
21. Rothman K, Greenland S, Lash TL (2008) Modern epidemiology. Wolters Kluwer Health. 3rd edn (Lippincott Williams & Wilkins: Philadelphia, PA, USA.
22. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
23. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16: 1160-1166.
24. WHO (2010) Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDDs Assignment 2011: Oslo, Norway.
25. Yu O, Boudreau DM, Buist DS, Miglioretti DL (2009) Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control 20: 609-616.